Linked Life Data

18202421

Source:http://linkedlifedata.com/resource/pubmed/id/18202421

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-1-18
pubmed:abstractText
Tumor shrinkage categorized as complete response (CR) or partial response (PR) is a fundamental efficacy measure for new cancer treatments and often considered a surrogate for overall survival. However, for any given treatment, many more patients typically achieve stable disease (SD) or have progressive disease (PD) than achieve response. We hypothesized that PD (or its converse, disease control rate [DCR], consisting of CR, PR, SD) is a stronger predictor of survival than response alone in advanced non-small-cell lung cancer (NSCLC), and that this determination might be assessable early on during therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
463-7
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
pubmed:affiliation
University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial